ATE489139T1 - Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin - Google Patents

Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin

Info

Publication number
ATE489139T1
ATE489139T1 AT06793626T AT06793626T ATE489139T1 AT E489139 T1 ATE489139 T1 AT E489139T1 AT 06793626 T AT06793626 T AT 06793626T AT 06793626 T AT06793626 T AT 06793626T AT E489139 T1 ATE489139 T1 AT E489139T1
Authority
AT
Austria
Prior art keywords
hccs
treatment
conjugate
doxorubicin
receptor
Prior art date
Application number
AT06793626T
Other languages
English (en)
Inventor
Luigi Fiume
Stefano Giuseppina Di
Original Assignee
Uni Di Bologna Dipartimento Di Patologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Di Bologna Dipartimento Di Patologia filed Critical Uni Di Bologna Dipartimento Di Patologia
Application granted granted Critical
Publication of ATE489139T1 publication Critical patent/ATE489139T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06793626T 2005-09-20 2006-09-19 Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin ATE489139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001743A ITMI20051743A1 (it) 2005-09-20 2005-09-20 Uso di coniugati della doxorubicina con albumina lattosaminata
PCT/EP2006/066489 WO2007039448A2 (en) 2005-09-20 2006-09-19 Use of conjugates of doxorubicin with lactosaminated albumin

Publications (1)

Publication Number Publication Date
ATE489139T1 true ATE489139T1 (de) 2010-12-15

Family

ID=37665721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06793626T ATE489139T1 (de) 2005-09-20 2006-09-19 Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin

Country Status (8)

Country Link
US (1) US20080227710A1 (de)
EP (1) EP1937310B8 (de)
CN (1) CN101267842A (de)
AT (1) ATE489139T1 (de)
DE (1) DE602006018499D1 (de)
ES (1) ES2357031T3 (de)
IT (1) ITMI20051743A1 (de)
WO (1) WO2007039448A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040928A1 (it) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
CN103656659B (zh) * 2012-09-26 2016-01-06 包骏 一种靶向载体、抗肿瘤药物及其应用
CN106344930B (zh) * 2015-07-16 2021-08-17 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的短肽阿霉素的制备和用途
RU2696096C2 (ru) * 2017-12-07 2019-07-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Низкомолекулярные конъюгаты противоопухолевых агентов и высокоселективных лигандов асиалогликопротеинового рецептора для терапии онкологических патологий печени
CN108671238A (zh) * 2018-05-14 2018-10-19 江苏医药职业学院 一种联合治疗高肿瘤渗透性白蛋白纳米系统的制备方法
CN109157662B (zh) * 2018-06-06 2021-07-20 北京大学 一种人血清白蛋白-阿霉素交联物纳米颗粒及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07507794A (ja) * 1992-06-17 1995-08-31 アドバンスド・マグネティクス・インク アラビノガラクタン誘導体及びその使用
ITMI20040928A1 (it) * 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
CN101137398B (zh) * 2005-01-05 2012-07-04 得克萨斯大学体系董事会 用于双重显像和放射化疗的缀合物：组合物、生产和应用

Also Published As

Publication number Publication date
EP1937310B8 (de) 2011-07-13
WO2007039448A3 (en) 2007-05-31
CN101267842A (zh) 2008-09-17
ITMI20051743A1 (it) 2007-03-21
WO2007039448A2 (en) 2007-04-12
EP1937310B1 (de) 2010-11-24
EP1937310A2 (de) 2008-07-02
DE602006018499D1 (de) 2011-01-05
ES2357031T3 (es) 2011-04-15
US20080227710A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO2016077840A3 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
ATE502053T1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
EP3838298A3 (de) Psma-bindungsliganden-linker-konjugate und anwendungsverfahren
MX2011009281A (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12.
LUC00011I2 (de)
WO2010066803A3 (en) Human antibodies against human tissue factor
EP3301117A3 (de) Spezifische bindeproteine und deren verwendungen
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
EP2175879A4 (de) Behandlung von erkrankungen im zusammenhang mit prion-protein
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
RU2017132324A (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
MX2021013391A (es) Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
MX2021003295A (es) Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
WO2009138396A3 (en) Conjugates for the treatment of mesothelioma
DE602006018499D1 (de) Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties